DSCSA Audit Readiness: How Wholesale Distributors Can Prove Compliance Beyond Process Documentation

FDA enforcement of DSCSA transaction verification requirements began August 27, 2025, shifting compliance from a process question to a documentation question. Wholesale drug distributors now face the operational gap between maintaining ATP processes and producing audit-ready evidence that those processes were executed correctly across every transaction.

Regulatory Context

The Drug Supply Chain Security Act (Pub. L. 113-54, enacted November 27, 2013) established transaction-level tracking requirements for prescription drugs moving through the U.S. supply chain. Under 21 CFR Part 1271, wholesale distributors must verify the Authorized Trading Partner (ATP) status of all entities from whom they receive product and to whom they distribute product.

The statute's enhanced drug distribution security provisions became enforceable on November 27, 2023, but FDA delayed active enforcement. As of August 27, 2025, FDA began inspection activity focused on verifying that wholesale distributors maintain systems capable of producing transaction-level documentation on demand.

What Changed

Prior to August 2025, wholesale distributors demonstrated DSCSA compliance primarily through process documentation: written SOPs, system architecture diagrams, and vendor contracts containing ATP language. This approach satisfied baseline compliance but did not test the critical question: can the distributor produce transaction-level proof that ATP verification occurred for a specific serial number on a specific date?

The shift to active enforcement requires distributors to demonstrate three capabilities:

1. Transaction-level ATP verification records — Documentation that trading partner status was verified before each transaction, not just at onboarding
2. Serialized product history — The ability to produce the complete chain of custody for any NDC/serial number combination in inventory
3. Exception handling records — Evidence that transactions failing ATP verification were quarantined and resolved according to documented procedures

FDA inspections now include requests for production records tied to specific serial numbers. An inspector may select a product currently in inventory and request documentation proving:

• The distributor from whom it was received was an ATP at the time of receipt
• ATP verification occurred before the product was accepted into inventory
• Transaction Information (TI), Transaction History (TH), and Transaction Statement (TS) were received and matched to the physical product
• If distributed onward, the receiving entity was verified as an ATP before shipment

Operational Implications for Wholesale Distributors

The documentation standard creates three pressure points for wholesale drug distributors:

System validation requirements. WMS, ERP, and ATP verification systems must generate and retain transaction-level records. Many distributors implemented DSCSA compliance through bolt-on verification tools that check ATP status but do not create auditable logs linking specific verification events to specific transaction documents. Audit readiness requires logs that tie ATP verification timestamps to inbound shipment records and outbound customer orders.

Data retention architecture. DSCSA requires six-year retention of transaction records (21 CFR 1271.155(a)(3)). Distributors relying on third-party ATP verification services must confirm that verification event data is retained in a format that can be correlated with internal transaction records. If the verification service only stores "current ATP status" without historical verification logs, the distributor cannot prove ATP verification occurred at the time of a transaction from three years ago.

Cross-system reconciliation. Proving compliance requires correlating data across purchasing systems (TI/TH/TS receipt), ATP verification systems (trading partner status at transaction time), warehouse management systems (product receipt and putaway), and distribution systems (outbound shipment records). Distributors using separate systems for these functions must demonstrate that serial number data flows consistently across all systems and that verification status can be reconstructed from system logs.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors, 3PLs, and cold chain providers across 51 jurisdictions. The average compliance score of 51/100 reflects a critical gap: while 1,234 entities (97%) hold active FDA registration — a baseline DSCSA requirement — only 63 entities hold NABP accreditation, the industry's primary third-party verification of DSCSA-compliant systems and processes.

The score distribution reveals audit readiness risk across the industry. Of the 1,275 tracked entities:

• 28 (2%) score in the "Excellent" tier (76-100 points) — entities with comprehensive licensure, NABP accreditation, and clean enforcement records
• 281 (22%) score "Good" (61-75 points) — broad state licensure but lacking NABP verification
• 919 (72%) score "Fair" (41-60 points) — the majority of the industry, holding basic FDA registration and regional licenses but without third-party process validation
• 47 (4%) score "Poor" or "Minimal" (0-40 points) — entities with limited licensure coverage or enforcement actions on record

73 entities in the directory have FDA recalls on record, indicating prior supply chain documentation failures. Under the current enforcement posture, these entities face elevated inspection risk. Distributors qualifying trading partners should verify that ATP verification systems log not only current compliance status but historical verification events tied to specific transactions.

Practical Guidance for QA and Procurement Teams

• Audit your ATP verification system architecture. Confirm that your verification tool creates timestamped logs of verification events, not just a snapshot of current trading partner status. Request documentation from your vendor showing that verification event data is retained for six years and can be exported with transaction identifiers (PO number, shipment ID, or serial number).

• Test cross-system reconciliation now. Select 10 serial numbers currently in inventory. Attempt to produce the complete documentation chain: ATP verification log showing the supplier was verified before receipt, TI/TH/TS documents received from that supplier, WMS receipt record showing the serial number was accepted, and (if distributed) the outbound shipment record and receiving customer's ATP verification log. If any link in this chain cannot be produced, the system is not audit-ready.

• Verify trading partner compliance posture. Use the ColdChainCheck directory to review the compliance scores of your top 20 suppliers and customers. Entities scoring below 50 may lack the systems infrastructure to provide transaction-level documentation if FDA requests supply chain verification during an investigation.

• Document exception handling. If your ATP verification system flags a transaction (expired license, suspended registration, no NABP accreditation), ensure the quarantine and resolution process creates a retrievable record. FDA inspections will specifically request examples of transactions that failed verification and how they were handled.

ColdChainCheck continuously monitors FDA enforcement actions, state board disciplinary records, and NABP accreditation status changes. For detailed requirements on transaction documentation and ATP verification workflows, see the DSCSA Compliance Checklist for Wholesale Distributors.

Disclaimer: This article presents publicly available regulatory information for informational purposes only and does not constitute legal or compliance advice. Wholesale distributors should consult qualified legal counsel and regulatory advisors to assess their specific DSCSA audit preparation requirements.